Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer

详细信息    查看全文

• 作者：Giovannalberto Pini (1) (2)
  Justin Collins (1)
  Pirus Ghadjar (3)
  Peter Wiklund (1)
  
  1. Karolinska Institute ; Department of Molecular Medicine and Surgery ; Section of Urology ; Solna ; Stockholm ; Sweden
  2. UroClinic AB Sverige ; Robotic Surgery ; Sophiahemmet Hospital ; 171 76 ; Stockholm ; Sweden
  3. Department of Radiation Oncology and Radiotherapy ; Charit茅 Universit盲tsmedizin Berlin ; Berlin ; Germany
  
• 关键词：Active surveillance ; Erectile dysfunction ; Localised prostate cancer ; Prostate ; specific antigen testing ; Prostate ; specific antigen screening ; Radical prostatectomy
• 刊名：Current Urology Reports
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：16
• 期：5
• 全文大小：882 KB
• 参考文献：1. Heidenreich, A, Bastian, PJ, Bellmunt, J, Bolla, M, Joniau, S, Kwast, T (2014) European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65: pp. 124-37 CrossRef
  2. Makarov, DV, Trock, BJ, Humphreys, EB (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69: pp. 1095-101 CrossRef
  3. Carter, HB, Albertsen, PC, Barry, MJ (2013) Early detection of prostate cancer: AUA guidelines. J Urol 190: pp. 419-26 CrossRef
  4. Schr枚der, FH, Hugosson, J, Roobol, MJ, Tammela, TL, Zappa, M (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13聽years of follow-up. Lancet.
  5. Muntener, M, Epstein, JI, Hernandez, DJ, Gonzalgo, ML, Mangold, L, Humphreys, E (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53: pp. 767-75 CrossRef
  6. Colaco, M, Sandberg, J, Badlani, G (2013) Influencing factors leading to malpractice litigation in radical prostatectomy. J Urol.
  7. Andriole, GL, Crawford, ED, Grubb, RL (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13聽years of follow-up. J Natl Cancer Inst 104: pp. 125-32 CrossRef
  8. Ilic, D, O鈥機onnor, D, Green, S, Wilt, T (2007) Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 18: pp. 279-85 CrossRef
  9. Draisma, G, Boer, R, Otto, SJ, Cruijsen, IW, Damhuis, RA, Schroder, FH (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 95: pp. 868-78 CrossRef
  10. Edwards, A, Hood, K, Matthews, E (2000) The effectiveness of one-to-one risk communication interventions in health care: a systematic review. Med Decis Mak 20: pp. 290-7 CrossRef
  11. Fridriksson, J, Gunseus, K, Stattin, P (2012) Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: a study from the National Prostate Cancer Register (NPCR) of Sweden. Scand J Urol Nephrol 46: pp. 326-31 CrossRef
  12. Yatani, R, Chigusa, I, Akazaki, K (1982) Geographic pathology of latent prostatic carcinoma. Int J Cancer 29: pp. 611-6 CrossRef
  13. Heidenreich, A, Abrahamsson, PA, Artibani, W (2013) Early detection of prostate cancer: European association of urology recommendation. Eur Urol 64: pp. 347-54 CrossRef
  14. National Comprehensive Cancer Network, Prostata cancer guideline version 1.2015, http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. / Latest NCCN guideline for PCa.
  15. Bratt, O (2002) Hereditary prostate cancer: clinical aspects. J Urol 168: pp. 906-13 CrossRef
  16. Alvarez-Cubero, MJ, Saiz, M, Martinez-Gonzalez, LJ, Alvarez, JC, Lorente, JA, Cozar, JM (2013) Genetic analysis of the principal genes related to prostate cancer: a review. Urol Oncol 31: pp. 1419-29 CrossRef
  17. Kozarewa, I, Fenwick, K, Assiotis, I, Barrowdale, D, Govindasami, K, Guy, M (2014) Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer 110: pp. 1663-72 CrossRef
  18. Eeles, RA, Olama, AA, Benlloch, S (2013) Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45: pp. 385-91 CrossRef
  19. Center, MM, Jemal, A, Lortet-Tieulent, J (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61: pp. 1079-92 CrossRef
  20. Cuzick, J, Thorat, MA, Andriole, G, Brawley, OW, Brown, PH, Culig, Z (2014) Prevention and early detection of prostate cancer. Lancet Oncol 15: pp. e484-92 CrossRef
  21. Sutcliff ES, Neace C, Magnuson NS, Reeves R, Alderete JF. Trichomonosis, a common curable STI, and prostate carcinogenesis鈥攁 proposed molecular mechanism. PLoS Pathog. 2012;8.
  22. Esposito, K, Chiodini, P, Capuano, A (2013) Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest 36: pp. 132-9 CrossRef
  23. Discacciati, A, Wolk, A (2014) Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res 202: pp. 27-37 CrossRef
  24. Masko, EM, Allott, EH, Freedland, SJ (2013) The relationship between nutrition and prostate cancer: is more always better?. Eur Urol 63: pp. 810-20 CrossRef
  25. Roddam, AW, Allen, NE, Appleby, P (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: pp. 461-71 CrossRef
  26. Redman, MW, Tangen, CM, Goodman, PJ, Lucia, MS, Coltman, CA, Thompson, IM (2008) Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 1: pp. 174-81 CrossRef
  27. Thompson, IM, Goodman, PJ, Tangen, CM (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: pp. 215-24 CrossRef
  28. Andriole, GL, Bostwick, DG, Brawley, OW (2010) and the REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: pp. 1192-202 CrossRef
  29. Marberger, M, Freedland, SJ, Andriole, GL (2012) Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 109: pp. 1162-9 CrossRef
  30. Rothwell, PM, Fowkes, FG, Belch, JF, Ogawa, H, Warlow, CP, Meade, TW (2011) Eff ect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: pp. 31-41 CrossRef
  31. Loeb, S, Vellekoop, A, Ahmed, HU, Catto, J, Emberton, M, Nam, R (2013) Systematic review of complications of prostate biopsy. Eur Urol 64: pp. 876-92 CrossRef
  32. Welch, HG, Albertsen, PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986鈥?005. J Natl Cancer Inst 101: pp. 1325-9 CrossRef
  33. Loeb, S, Catalona, WJ (2009) What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels?. Nat Clin Pract Urol 6: pp. 68-9 CrossRef
  34. Stephan, C, K枚pke, T, Semjonow, A, Lein, M, Deger, S, Schrader, M (2009) Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?. Clin Chem Lab Med 47: pp. 1325-31 CrossRef
  35. Thompson, IM, Pauler, DK, Goodman, PJ (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level <4.0聽ng per millilitre. N Engl J Med 350: pp. 2239-46 CrossRef
  36. Catalona, WJ, Partin, AW, Slawin, KM, Brawer, MK, Flanigan, RC, Patel, A (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: pp. 1542-7 CrossRef
  37. Perdon脿, S, Bruzzese, D, Ferro, M (2013) Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 73: pp. 227-35 CrossRef
  38. Vedder, MM, Bekker-Grob, EW, Lilja, HG, Vickers, AJ, Leenders, GJ, Steyerberg, EW (2014) The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol.
  39. Leyten, GH, Hessels, D, Jannink, SA (2014) Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 65: pp. 534-42 CrossRef
  40. Stephenson, SK, Chang, EK, Marks, LS (2014) Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am 41: pp. 315-26 CrossRef
  41. Bouye, S, Potiron, E, Puech, P, Leroy, X, Lemaitre, L, Villers, A (2009) Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. Prostate 69: pp. 105-13 CrossRef
  42. Walz, J, Bladou, F, Rousseau, B, Laroche, J, Salem, N, Gravis, G (2012) Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. Urology 79: pp. 546-51 CrossRef
  43. Wilt, TJ, Brawer, MK, Jones, KM (2012) Radical prostatectomy versus observation for localized prostate cancer (PIVOT). N Engl J Med 367: pp. 203-13 CrossRef
  44. Droz J-P, Aapro M, Balducci L, et al. Management of prostate cancer in senior adults: updated recommendations of a working group of the International Society of Geriatric Oncology (SIOG). The Lancet Oncology 2014. In press. / Latest indication from SIOG in the management of PCa in the elderly patients.
  45. Chodak, GW, Thisted, RA, Gerber, GS (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: pp. 242-8 CrossRef
  46. Klotz, L, Zhang, L, Lam, A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Onco 28: pp. 126-31 CrossRef
  47. Johansson, JE, Andr茅n, O, Andersson, SO (2004) Natural history of early, localized prostate cancer. JAMA 291: pp. 2713-9 CrossRef
  48. Moore, CM, Kasivisvanathan, V, Eggener, S (2013) START Consortium. Standards of reporting for MRI targeted biopsy studies (START) of the prostate: recommendations from an international working group. Eur Urol 64: pp. 544-52 CrossRef
  49. Bul, M, Zhu, X, Valdagni, R (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63: pp. 597-603 CrossRef
  50. Bergh, RC, Korfage, IJ, Bangma, CH (2012) Psychological aspects of active surveillance. Curr Opin Urol 22: pp. 237-42 CrossRef
  51. Braun, K, Ahallal, Y, Sjoberg, DD (2014) Effect of repeated prostate biopsies on erectile function in men on active surveillance for prostate cancer. J Urol 191: pp. 744-9 CrossRef
  52. Bill-Axelson, A, Holmberg, L, Ruutu, M (2011) Radical prostatectomy versus watchful waiting in early prostate cancer (SPCG-4). N Engl J Med 364: pp. 1708-17 CrossRef
  53. Epstein, JI, Feng, Z, Trock, BJ, Pierorazio, PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61: pp. 1019-24 CrossRef
  54. Graversen, PH, Nielsen, KT, Gasser, TC (1990) Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 36: pp. 493-8 CrossRef
  55. Ficarra, V, Novara, G, Ahlering, TE (2012) Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 62: pp. 418-30 CrossRef
  56. Ficarra, V, Ficarra, V, Novara, G, Rosen, RC, Artibani, W, Carroll, PR (2012) Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 62: pp. 405-17 CrossRef
  57. Briganti, A, Larcher, A, Abdollah, F (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61: pp. 480-7 CrossRef
  58. Spratt, DE, Pei, X, Yamada, J, Kollmeier, MA, Cox, B, Zelefsky, MJ (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol, Biol, Phys 85: pp. 686-92 CrossRef
  59. Zelefsky, MJ, Kollmeier, M, Cox, B, Fidaleo, A, Sperling, D, Pei, X (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol, Biol, Phys 84: pp. 125-9 CrossRef
  60. Viani, GA, Stefano, EJ, Afonso, SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol, Biol, Phys 74: pp. 1405-18 CrossRef
  61. Prada, PJ, Juan, G, Gonz谩lez-Su谩rez, H, Fern谩ndez, J, Jimenez, I, Am贸n, J (2010) Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10聽years of follow-up with localized prostate cancer treated by permanent iodine implants. BJU Int 106: pp. 32-6 CrossRef
  62. Ghadjar, P, Jackson, A, Spratt, DE, Oh, JH, Munck, AF, Rosensch枚ld, P (2013) Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. Eur Urol 64: pp. 931-8 CrossRef
  63. Ghadjar, P, Oesch, SL, Rentsch, CA, Isaak, B, Cihoric, N, Manser, P (2014) Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Radiat Oncol 9: pp. 122 CrossRef
  64. Buyyounouski, MK, Price, RA, Harris, EE, Miller, R, Tom茅, W, Schefter, T (2010) Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol, Biol, Phys 76: pp. 1297-304 CrossRef
  65. Sooriakumaran, P, Nyberg, T, Akre, O, Haendler, L, Heus, I, Olsson, M (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348: pp. g1502 CrossRef
  66. D鈥橝mico, AV, Whittington, R, Malkowicz, SB, Schultz, D, Blank, K, Broderick, GA (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: pp. 969-74 CrossRef
  67. Zelefsky, MJ, Eastham, JA, Cronin, AM, Fuks, Z, Zhang, Z, Yamada, Y (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28: pp. 1508-13 CrossRef
  68. Bahn, DK, Lee, F, Baldalament, R (2002) Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60: pp. 3-11 CrossRef
  69. Crouzet, S, Chapelon, JY, Rouvi猫re, O (2013) Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol.
  70. Pfeiffer, D, Berger, J, Gross, AJ (2012) Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes. BJU Int 110: pp. 1702-7 CrossRef
  71. Graversen, PH, Nielsen, KT, Gasser, TC (1990) Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 36: pp. 493-8 CrossRef
  72. D鈥橝mico, AV, Chen, MH, Renshaw, AA, Loffredo, M, Kantoff, PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299: pp. 289-95
  73. Zumsteg, ZS, Spratt, DE, Pei, X, Yamada, Y, Kalikstein, A, Kuk, D (2013) Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int J Radiat Oncol, Biol, Phys 85: pp. 1012-7 CrossRef
  74. Lawton, CA, Bae, K, Pilepich, M, Hanks, G, Shipley, W (2008) Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol, Biol, Phys 70: pp. 437-41 CrossRef
  75. Nanda, A, Chen, MH, Braccioforte, MH, Moran, BJ, D鈥橝mico, AV (2009) Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302: pp. 866-73 CrossRef
  76. Spratt, DE, Zumsteg, ZS, Ghadjar, P, Kollmeier, MA, Pei, X, Cohen, G (2014) Comparison of high-dose (86.4聽Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 114: pp. 360-7
  77. Buyyounouski, MK, Price, RA, Harris, EE, Miller, R, Tom茅, W, Schefter, T (2010) Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol, Biol, Phys 76: pp. 1297-304 CrossRef
  78. Pommier, P, Chabaud, S, Lagrange, JL, Richaud, P, Lesaunier, F, Le, PE (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25: pp. 5366-73 CrossRef
  79. Lawton, CA, DeSilvio, M, Roach, M, Uhl, V, Kirsch, R, Seider, M (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol, Biol, Phys 69: pp. 646-55 CrossRef
  80. Donohue, JF, Bianco, FJ, Kuroiwa, K (2006) Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 176: pp. 991-5 CrossRef
  81. Ji, J, Yuan, H, Wang, L (2012) Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study. J Surg Res 178: pp. 779-84 CrossRef
  82. Yuh, B, Artibani, W, Heidenreich, A, Kimm, S, Menon, M, Novara, G (2014) The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol 65: pp. 918-27 CrossRef
  83. Bolla, M, Collette, L, Blank, L, Warde, P, Dubois, JB, Mirimanoff, RO (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: pp. 103-6 CrossRef
  84. Bolla, M, Tienhoven, G, Warde, P, Dubois, JB, Mirimanoff, RO, Storme, G (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11: pp. 1066-73 CrossRef
  85. Widmark, A, Klepp, O, Solberg, A, Damber, JE, Angelsen, A, Fransson, P (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373: pp. 301-8 CrossRef
  86. Warde, P, Mason, M, Ding, K, Kirkbride, P, Brundage, M, Cowan, R (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378: pp. 2104-11 CrossRef
  
• 刊物主题：Urology/Andrology; Nephrology;
• 出版者：Springer US
• ISSN：1534-6285

文摘

The main objective of this review is to summarise, for primary and secondary care doctors, the management options and current supporting evidence for clinically localised prostate cancer. We review all aspects of management including current guidelines on early cancer detection and the importance of informed consent on PSA-based screening and assess the most common treatment options and the evidence for managing patients with low-, medium-, and high-risk disease.